In the above-mentioned study by Singh et al.33 in anti-TNF- and vedolizumab-treated patients with IBD of all ages the authors also found a higher rate of serious infections in frail patients, but after adjusting for confounders this risk was no longer significant. The gene discussed is TNF; the disease is infection.